Misplaced Pages

Legius syndrome
Other names	Neurofibromatosis 1-like syndrome
This condition is inherited in an autosomal dominant manner.
Symptoms	café au lait spots; +/- learning disabilities
Usual onset	at birth
Causes	Mutations in the SPRED1 gene
Diagnostic method	Clinical findings, Genetic test
Differential diagnosis	neurofibromatosis type I
Treatment	Physical therapy, Speech therapy
Prognosis	good
Frequency	rare (estimated at 1:46,000-1:75,000)

Legius syndrome (LS) is an autosomal dominant condition characterized by cafe au lait spots. It was first described in 2007 and is often mistaken for neurofibromatosis type I. It is caused by mutations in the SPRED1 gene. It is also known as neurofibromatosis type 1-like syndrome.

Symptoms and signs

Nearly all individuals with Legius syndrome show multiple café au lait spots on their skin. Symptoms may include:

• Freckles in the axillary and inguinal skin fold
• Lipomas, developing in adulthood
• Macrocephaly
• Learning disabilities
• Attention deficit hyperactivity disorder
• Developmental delay

Features common in neurofibromatosis – like Lisch nodules (iris hamartomas diagnosed on slit lamp exam), bone abnormalities, neurofibromas, optic pathway gliomas and malignant peripheral nerve sheath tumors – are absent in Legius syndrome.

Cause

Legius syndrome is a phakomatosis and a RASopathy, a developmental syndrome due to germline mutations in genes. The condition is autosomal dominant in regards to inheritance and caused by mutations to the SPRED1 gene at chromosome 15, specifically 15q14 (or (GRCh38): 15:38,252,086-38,357,248). The gene in question demonstrates almost 100 mutations.

Mechanism

A mutated SPRED1 protein adversely regulates Ras-MAPK signaling, which is a chain of proteins in a cell that sends signals from the surface of a cell to the nucleus which in turn causes the symptoms of this condition.

Diagnosis

Genetic testing is necessary to identify the syndrome. The DNA test is necessary sometimes, because symptoms may not be sufficient to definitely diagnose this condition.

Differential diagnosis

The symptoms of Legius syndrome and neurofibromatosis type I are very similar; An important difference between Legius syndrome and neurofibromatosis type I is the absence of tumor growths Lisch nodules and neurofibromas which are common in neurofibromatosis type I.

A genetic test is often the only way to make sure a person has Legius syndrome and not neurofibromatosis type I; the similarity of symptoms stem from the fact that the different genes affected in the two syndromes code for proteins that carry out a similar task in the same reaction pathway.

Treatment

Management of Legius syndrome is done via the following:

• Physical therapy
• Speech therapy
• Pharmacologic therapy (e.g. methylphenidate for attention deficit hyperactivity disorder)

The prognosis of this condition is generally considered good with appropriate treatment.

See also

• List of cutaneous conditions
• List of genes mutated in cutaneous conditions

References

1. ^ RESERVED, INSERM US14 -- ALL RIGHTS. "Orphanet: Legius syndrome". www.orpha.net. Retrieved 2017-06-01.{{cite web}}: CS1 maint: numeric names: authors list (link)
2. ^ Stevenson, David; Viskochil, David; Mao, Rong (1993). "Legius Syndrome". GeneReviews. PMID 20945555. Retrieved 1 June 2017.update 2015
3. ^ "Legius syndrome", Genetics Home Reference, National Institutes of Health
4. ^ "Legius syndrome | Genetic and Rare Diseases Information Center". rarediseases.info.nih.gov. Retrieved 2017-06-01.
5. "SPRED1", Genetics Home Reference, National Institutes of Health
6. "Legius Syndrome Often Mistaken for Neurofibromatosis Type 1", by Allison Gandley, November 18, 2009, Medscape
7. ^ "OMIM Entry - # 611431 - LEGIUS SYNDROME". omim.org. Retrieved 2017-06-01.
8. Rosser, Tena (February 2018). "Neurocutaneous Disorders". Continuum (Minneapolis, Minn.). 24 (1, Child Neurology): 96–129. doi:10.1212/CON.0000000000000562. ISSN 1538-6899. PMID 29432239. S2CID 4107835.
9. Tidyman, William (2009). "The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation". Current Opinion in Genetics & Development. 19 (3): 230–236. doi:10.1016/j.gde.2009.04.001. PMC 2743116. PMID 19467855.
10. "OMIM Entry - * 609291 - SPROUTY-RELATED EVH1 DOMAIN-CONTAINING PROTEIN 1; SPRED1". www.omim.org. Retrieved 2017-06-01.
11. "Homo sapiens sprouty related EVH1 domain containing 1 (SPRED1), RefSeq - Nucleotide - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-06-01.
12. Molina, Julian R.; Adjei, Alex A. (2006-01-01). "The Ras/Raf/MAPK Pathway". Journal of Thoracic Oncology. 1 (1): 7–9. doi:10.1016/S1556-0864(15)31506-9. PMID 17409820.
13. "SPRED1 sprouty related EVH1 domain containing 1 - Gene - GTR - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-06-01.
14. Storebø, Ole Jakob; Storm, Maja Rosenberg Overby; Pereira Ribeiro, Johanne; Skoog, Maria; Groth, Camilla; Callesen, Henriette E.; Schaug, Julie Perrine; Darling Rasmussen, Pernille; Huus, Christel-Mie L.; Zwi, Morris; Kirubakaran, Richard; Simonsen, Erik; Gluud, Christian (2023-03-27). "Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)". The Cochrane Database of Systematic Reviews. 2023 (3): CD009885. doi:10.1002/14651858.CD009885.pub3. ISSN 1469-493X. PMC 10042435. PMID 36971690.

Further reading

• MD, Robert P. Erickson; PhD, Anthony J. Wynshaw-Boris MD (2016). Epstein's Inborn Errors of Development: The Molecular Basis of Clinical Disorders of Morphogenesis. Oxford University Press. ISBN 9780190275426. Retrieved 1 June 2017.
• Zhang, Jia (2016). "Molecular screening strategies for NF1-like syndromes with café-au-lait macules". Molecular Medicine Reports. 14 (5): 4023–4029. doi:10.3892/mmr.2016.5760. PMC 5112360. PMID 27666661. Review

External links

• PubMed

• Genodermatoses
• Neuro-cardio-facial-cutaneous syndromes
• RASopathies